CB-103 is under clinical development by Cellestia Biotech and currently in Phase II for Adenoid Cystic Carcinoma (ACC). According to GlobalData, Phase II drugs for Adenoid Cystic Carcinoma (ACC) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CB-103 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CB-103 overview
CB-103 is under development for the treatment of notch dependent solid tumors including T-cell acute lymphoblastic leukemia, graft versus host disease, r/r T-cell acute lymphoblastic leukemia (T-ALL), and adenoid cystic carcinoma (ACC). The drug candidate is administered through oral route, and it is formulated as capsules. It acts by targeting the Notch intracellular domain.
It was under development for the treatment of rhabdomyosarcoma, fibrosarcoma, liposarcoma, cholangiocarcinoma, Colorectal Cancer, HER 2 negative breast cancer.
It was under development for the treatment of Metastatic Colorectal Cancer, Gastric Cancer, Metastatic Ovarian Cancer , Cervical Cancer, Non-Small Cell Lung Cancer, Metastatic Melanoma , Osteosarcoma, Glioblastoma Multiforme (GBM), Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Marginal Zone B-cell Lymphoma , Splenic Marginal Zone B-Cell Lymphoma, Mantle Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL), Peripheral T-Cell Lymphomas (PTCL), CNS Lymphoma, Triple-Negative Breast Cancer (TNBC) and Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).
Cellestia Biotech overview
Cellestia Biotech (Cellestia) is a company that develops therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. The company’s pipeline products include CB-103 which targets T-cell acute lymphoblastic leukemia; CB-103+VEGFRi for adenoid cystic carcinoma; CB-103+SoC treats Graft-versus-host disease prophylaxis; CB-401, CB-433 for auto immune diseases. Its therapeutic areas include chronic autoimmune indications such as psoriasis, Sjogren’s syndrome, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and giant cell arteritisCellestia. Biotech is headquartered in Basel, Switzerland.
For a complete picture of CB-103’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
